Angelika is the Institute’s Technology Translation Director & Chief Operating Officer, applying her technology and entrepreneurial business development experience to steer the Institute’s technology translation engine in diverse areas of research and technology development and to integrate the Institute’s business development and technology commercialization efforts. She earned her Ph.D. in organic chemistry at the University of Geneva, Switzerland, and gained postdoctoral experience in the laboratory of Professor Gregory Verdine at Harvard University. Following her academic training, Angelika pursued her M.B.A. at Suffolk University, Boston, and subsequently held leadership positions at Ironwood Pharmaceuticals, and most recently at Catabasis Pharmaceuticals in Cambridge, MA, where she was Senior Vice President of Product Development. Her industry experience enabled her to gain a deep understanding of the processes involved in developing and de-risking therapeutic products from pre-clinical stages to the clinical market, including the regulatory approval process. Between 2008 and 2019, she also served on the Board of Directors of Bridgewell, a health and human services non-profit organization serving a wide range of constituents in day programs, residential housing and clinical services.
Angelika Fretzen, Ph.D., M.B.A.
Technology Translation Director & Chief Operating Officer